GSK's Synflorix to be used for GAVI pneumococcal vaccines program in Pakistan

World’s largest pneumococcal mass vaccination program is expected to protect up to 4.8 million children in Pakistan from pneumococcal disease. Pakistan is the first GAVI eligible country in south Asia to introduce pneumococcal vaccines.

GlaxoSmithKline (LSE: GSK) said it welcomes the announcement from the GAVI Alliance that its pneumococcal vaccine, Synflorix, is to be introduced into the national immunization program in Pakistan.

The UK pharma giant will provide a minimum of 480 million doses of Synflorix to GAVI to help expand immunization programs against pneumococcal disease to 73 developing countries by 2023. By 2023, Synflorix may help to protect up to 160 million children in developing countries against pneumococcal disease. GSK says it has invested more than $400 million in a dedicated manufacturing plant in Singapore that will support growing demand for this vaccine in the coming years.